None
Quote | Rexahn Pharmaceuticals Inc. (NYSE:RNN)
Last: | $ |
---|---|
Change Percent: | 0.19% |
Open: | $5.25 |
Close: | $5.24 |
High: | $5.44 |
Low: | $4.97 |
Volume: | 34,403 |
Last Trade Date Time: | 06/07/2019 04:56:26 pm |
News | Rexahn Pharmaceuticals Inc. (NYSE:RNN)
ROCKVILLE, Md., May 28, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat, today announced that it will voluntarily transfe...
Rexahn Pharmaceuticals (NYSEMKT: RNN ): Q1 GAAP EPS of -$0.62 beats by $0.39 . Cash, Cash Equivalents and Marketable Securities of $18.02M Press Release More news on: Rexahn Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, ,
Message Board Posts | Rexahn Pharmaceuticals Inc. (NYSE:RNN)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Rexahn Pharmaceuticals Inc. Company Name:
RNN Stock Symbol:
NYSE Market:
Rexahn Pharmaceuticals Inc. Website:
ROCKVILLE, Md., May 28, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat, today announced that it will voluntarily transfe...
ROCKVILLE, Md., May 13, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat, today announced financial results for the first ...
ROCKVILLE, Md. and SUZHOU, China, April 16, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage, biopharmaceutical company focused on oncology, and BioSense Global LLC, a New Jersey- and Suzhou, China-based biopharmaceutical company, today announced ...